The use of linezolid in the treatment of vancomycin-resistant enterococcal septicaemia in two patients with burn injuries

J. L. Atkins, N. Hidvegi, L. Teare, Peter Dziewulski

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Vancomycin-resistant enterococci (VRE) are multi-resistant micro-organisms that have emerged as important nosocomial pathogens during the last decade. Emergence of this organism has been blamed mainly on the increased and inappropriate use of antibiotics, in particular, the cephalosporins and the glycopeptide, vancomycin. Burns patients are highly vulnerable to acquiring VRE infections, being both debilitated and immunocompromised, and often receiving antibiotics that further diminish their intrinsic microbial flora. We report on two patients with large burn injuries who acquired vancomycin-resistant enterococcal septicaemia during their in-patient stay. Both patients were successfully treated using the antibiotic, linezolid. Linezolid is the first in a new class of antibiotics known as the oxazolidinones whose mode of action inhibits early bacterial protein synthesis. Linezolid has a spectrum of activity against Gram-positive micro-organisms including methicillin-resistant Staphylococcus aureus (MRSA) and VRE, and can provide a useful treatment alternative to the glycopeptides.

Original languageEnglish (US)
Pages (from-to)185-188
Number of pages4
JournalBurns
Volume28
Issue number2
DOIs
StatePublished - Mar 27 2002
Externally publishedYes

Fingerprint

Linezolid
Vancomycin
Sepsis
Anti-Bacterial Agents
Glycopeptides
Wounds and Injuries
Oxazolidinones
Bacterial Proteins
Cephalosporins
Therapeutics
Methicillin-Resistant Staphylococcus aureus
Infection

Keywords

  • Burns
  • Linezolid
  • Vancomycin-resistant enterococci

ASJC Scopus subject areas

  • Surgery
  • Emergency Medicine
  • Critical Care and Intensive Care Medicine

Cite this

The use of linezolid in the treatment of vancomycin-resistant enterococcal septicaemia in two patients with burn injuries. / Atkins, J. L.; Hidvegi, N.; Teare, L.; Dziewulski, Peter.

In: Burns, Vol. 28, No. 2, 27.03.2002, p. 185-188.

Research output: Contribution to journalArticle

@article{9d5d604968b548ae84c387c27bd5a18d,
title = "The use of linezolid in the treatment of vancomycin-resistant enterococcal septicaemia in two patients with burn injuries",
abstract = "Vancomycin-resistant enterococci (VRE) are multi-resistant micro-organisms that have emerged as important nosocomial pathogens during the last decade. Emergence of this organism has been blamed mainly on the increased and inappropriate use of antibiotics, in particular, the cephalosporins and the glycopeptide, vancomycin. Burns patients are highly vulnerable to acquiring VRE infections, being both debilitated and immunocompromised, and often receiving antibiotics that further diminish their intrinsic microbial flora. We report on two patients with large burn injuries who acquired vancomycin-resistant enterococcal septicaemia during their in-patient stay. Both patients were successfully treated using the antibiotic, linezolid. Linezolid is the first in a new class of antibiotics known as the oxazolidinones whose mode of action inhibits early bacterial protein synthesis. Linezolid has a spectrum of activity against Gram-positive micro-organisms including methicillin-resistant Staphylococcus aureus (MRSA) and VRE, and can provide a useful treatment alternative to the glycopeptides.",
keywords = "Burns, Linezolid, Vancomycin-resistant enterococci",
author = "Atkins, {J. L.} and N. Hidvegi and L. Teare and Peter Dziewulski",
year = "2002",
month = "3",
day = "27",
doi = "10.1016/S0305-4179(01)00082-1",
language = "English (US)",
volume = "28",
pages = "185--188",
journal = "Burns",
issn = "0305-4179",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - The use of linezolid in the treatment of vancomycin-resistant enterococcal septicaemia in two patients with burn injuries

AU - Atkins, J. L.

AU - Hidvegi, N.

AU - Teare, L.

AU - Dziewulski, Peter

PY - 2002/3/27

Y1 - 2002/3/27

N2 - Vancomycin-resistant enterococci (VRE) are multi-resistant micro-organisms that have emerged as important nosocomial pathogens during the last decade. Emergence of this organism has been blamed mainly on the increased and inappropriate use of antibiotics, in particular, the cephalosporins and the glycopeptide, vancomycin. Burns patients are highly vulnerable to acquiring VRE infections, being both debilitated and immunocompromised, and often receiving antibiotics that further diminish their intrinsic microbial flora. We report on two patients with large burn injuries who acquired vancomycin-resistant enterococcal septicaemia during their in-patient stay. Both patients were successfully treated using the antibiotic, linezolid. Linezolid is the first in a new class of antibiotics known as the oxazolidinones whose mode of action inhibits early bacterial protein synthesis. Linezolid has a spectrum of activity against Gram-positive micro-organisms including methicillin-resistant Staphylococcus aureus (MRSA) and VRE, and can provide a useful treatment alternative to the glycopeptides.

AB - Vancomycin-resistant enterococci (VRE) are multi-resistant micro-organisms that have emerged as important nosocomial pathogens during the last decade. Emergence of this organism has been blamed mainly on the increased and inappropriate use of antibiotics, in particular, the cephalosporins and the glycopeptide, vancomycin. Burns patients are highly vulnerable to acquiring VRE infections, being both debilitated and immunocompromised, and often receiving antibiotics that further diminish their intrinsic microbial flora. We report on two patients with large burn injuries who acquired vancomycin-resistant enterococcal septicaemia during their in-patient stay. Both patients were successfully treated using the antibiotic, linezolid. Linezolid is the first in a new class of antibiotics known as the oxazolidinones whose mode of action inhibits early bacterial protein synthesis. Linezolid has a spectrum of activity against Gram-positive micro-organisms including methicillin-resistant Staphylococcus aureus (MRSA) and VRE, and can provide a useful treatment alternative to the glycopeptides.

KW - Burns

KW - Linezolid

KW - Vancomycin-resistant enterococci

UR - http://www.scopus.com/inward/record.url?scp=0036125219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036125219&partnerID=8YFLogxK

U2 - 10.1016/S0305-4179(01)00082-1

DO - 10.1016/S0305-4179(01)00082-1

M3 - Article

VL - 28

SP - 185

EP - 188

JO - Burns

JF - Burns

SN - 0305-4179

IS - 2

ER -